Inovio Pharmaceuticals Inc. (INO)

2.50
0.01 0.20
NASDAQ : Health Technology
Prev Close 2.50
Open 2.50
Day Low/High 2.45 / 2.53
52 Wk Low/High 1.92 / 5.47
Volume 495.60K
Avg Volume 631.00K
Exchange NASDAQ
Shares Outstanding 100.01M
Market Cap 237.02M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

Last week was a busy one for the portfolio, as we made a number of trades and saw outsized gains in several positions.

Selling a Chunk of a Biotech and Upgrading a Stock

We're reducing our position in Inovio Pharmaceuticals and raising our rating on Hudson Technologies.

Stocks Under $10 Weekly Summary

We bought into some tech names last week as a rotation occurred in the sector.

Inovio Pharmaceuticals Promotes Dr. Laurent Humeau To Senior Vice President, Research & Development

Inovio Pharmaceuticals Promotes Dr. Laurent Humeau To Senior Vice President, Research & Development

New strategic position will guide product discovery  and scientific collaborations

Inovio Pharmaceuticals Appoints Wendy Yarno To Its Board Of Directors

Inovio Pharmaceuticals Appoints Wendy Yarno To Its Board Of Directors

Former Chief Marketing Officer at Merck Also Brings Women's Health Management Expertise

Stocks Under $10 Weekly Summary

For the second week in a row, we initiated a new position, this time in a security tech name.

Inovio's Further Analysis Of VGX-3100 Phase 2b Data Reveals Immune Correlates And Biomarker Signatures That Predicted Clinical Efficacy

Inovio's Further Analysis Of VGX-3100 Phase 2b Data Reveals Immune Correlates And Biomarker Signatures That Predicted Clinical Efficacy

Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product

Stocks Under $10 Weekly Summary

We initiated a new position for the portfolio during the shortened holiday trading week.

Interesting INO Call Options For January 2018

Interesting INO Call Options For January 2018

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the January 2018 expiration.

Stocks Under $10 Weekly Summary

We exited three biotech/pharma positions and added to two other holdings during a busy week for the portfolio.

Closing out of a Biotech Position

Enzo Biochem has had some worrying action in price.

Stocks Under $10 Weekly Summary

We exited two positions today following a tough week for small-cap stocks.

Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society For Immunotherapy Of Cancer Conference

Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society For Immunotherapy Of Cancer Conference

Inovio's cancer immunotherapies show antigen-specific T-cell stimulation in head and neck and other solid tumors

Cutting Inovio Pharma's Rating

We are looking to exit this name, maximizing exit value.

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.

Adding to a Pharma Position, and an Update on Portfolio Earnings

Earnings analysis on four stocks -- and we are increasing our ACRX position on this weakness.

Stocks Under $10 Weekly Summary

Last week, we increased our holdings in one position and added 2 Bullpen names.

Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma In Combination With Regeneron's PD-1 Inhibitor

Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma In Combination With Regeneron's PD-1 Inhibitor

Phase 1b/2a clinical trial combines Regeneron's PD-1 inhibitor cemiplimab and Inovio's T cell activator INO-5401 in brain cancer

Stocks Under $10 Weekly Summary

We used price declines to scale into several holdings as small-caps underperformed the overall market.

Inovio Pharmaceuticals is Now Oversold (INO)

Inovio Pharmaceuticals is Now Oversold (INO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of INO December 15th Options Trading

First Week of INO December 15th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.

Stocks Under $10 Weekly Summary

This week brings earnings from 5 portfolio holdings as the market continues to shrug off potential negatives.

Stocks Under $10 Weekly Summary

We took some profits and added a Bullpen name, among other moves, during a rough week for a few portfolio names.

Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy With A PD-L1 Checkpoint Inhibitor In Advanced Bladder Cancer

Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy With A PD-L1 Checkpoint Inhibitor In Advanced Bladder Cancer

Trial to evaluate Inovio's INO-5401 and Genentech's TECENTRIQ® in patients with metastatic bladder cancer

Adding to AcelRx on Weakness

I prefer to fight back on this one.

TheStreet Quant Rating: D- (Sell)